JP7254246B2 - デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法 - Google Patents

デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法 Download PDF

Info

Publication number
JP7254246B2
JP7254246B2 JP2022529556A JP2022529556A JP7254246B2 JP 7254246 B2 JP7254246 B2 JP 7254246B2 JP 2022529556 A JP2022529556 A JP 2022529556A JP 2022529556 A JP2022529556 A JP 2022529556A JP 7254246 B2 JP7254246 B2 JP 7254246B2
Authority
JP
Japan
Prior art keywords
methyl
trifluoromethyl
pyrimidin
pyrazol
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022529556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549739A (ja
Inventor
アレン，ジェニファー・アール
ベルトラーニ，ミケーラ
ブルボー，マシュー・ピー
ダムヤノバ，テオドーラ・ピー
リンガード，イアン
ミナッティ，アナ・イー
ビンチェッティ，パオロ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2022549739A publication Critical patent/JP2022549739A/ja
Priority to JP2023049452A priority Critical patent/JP7698676B2/ja
Application granted granted Critical
Publication of JP7254246B2 publication Critical patent/JP7254246B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022529556A 2019-11-25 2020-11-24 デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法 Active JP7254246B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023049452A JP7698676B2 (ja) 2019-11-25 2023-03-27 デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939821P 2019-11-25 2019-11-25
US62/939,821 2019-11-25
PCT/US2020/062020 WO2021108408A1 (en) 2019-11-25 2020-11-24 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023049452A Division JP7698676B2 (ja) 2019-11-25 2023-03-27 デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法

Publications (2)

Publication Number Publication Date
JP2022549739A JP2022549739A (ja) 2022-11-28
JP7254246B2 true JP7254246B2 (ja) 2023-04-07

Family

ID=73855555

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022529556A Active JP7254246B2 (ja) 2019-11-25 2020-11-24 デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法
JP2023049452A Active JP7698676B2 (ja) 2019-11-25 2023-03-27 デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023049452A Active JP7698676B2 (ja) 2019-11-25 2023-03-27 デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法

Country Status (21)

Country Link
US (3) US11512097B2 (OSRAM)
EP (1) EP4065223A1 (OSRAM)
JP (2) JP7254246B2 (OSRAM)
KR (2) KR20230154292A (OSRAM)
CN (2) CN118161500A (OSRAM)
AR (1) AR120556A1 (OSRAM)
AU (1) AU2020392087B2 (OSRAM)
BR (1) BR112022010054A2 (OSRAM)
CA (1) CA3162281A1 (OSRAM)
CL (2) CL2022001357A1 (OSRAM)
CO (1) CO2022008690A2 (OSRAM)
CR (1) CR20220308A (OSRAM)
IL (1) IL293191B2 (OSRAM)
JO (1) JOP20220125A1 (OSRAM)
MX (1) MX2022006281A (OSRAM)
PE (1) PE20231097A1 (OSRAM)
PH (1) PH12022551282A1 (OSRAM)
SA (1) SA522432710B1 (OSRAM)
TW (2) TWI815061B (OSRAM)
UY (1) UY38971A (OSRAM)
WO (1) WO2021108408A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023078418A (ja) * 2019-11-25 2023-06-06 アムジエン・インコーポレーテツド デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220510B2 (en) * 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
CN115557903A (zh) * 2022-09-27 2023-01-03 山东潍坊润丰化工股份有限公司 一种特草定的制备方法
EP4622648A1 (en) 2022-11-23 2025-10-01 Amgen Inc. Selection of patients for the treatment of fads1-mediated diseases or disorders using fads-1 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516321A (ja) 2009-01-27 2012-07-19 武田薬品工業株式会社 デルター５−デサチュラーゼ阻害薬

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
JP2641443B2 (ja) 1986-04-07 1997-08-13 クミアイ化学工業株式会社 ５Ｈ−１，３，４−チアジアゾロ〔３，２−ａ〕ピリミジン−５−オン誘導体及びこれを有効成分とする農園芸用殺菌剤
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
BR9713863A (pt) 1996-12-05 2000-03-14 Amgen Inc Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase
HK1047437B (en) 1999-10-15 2005-12-16 Neurocrine Biosciences, Inc. Gonadotropin releasing hormone receptor antagonists and their related methods of use
US6537998B1 (en) * 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
JP2004107228A (ja) 2002-09-17 2004-04-08 Nippon Nohyaku Co Ltd 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
KR20070091677A (ko) 2004-12-24 2007-09-11 아스트라제네카 아베 Ｃｃｒ2ｂ 길항제로서의 헤테로시클릭 화합물
DE602006015658D1 (de) 2005-06-27 2010-09-02 Amgen Inc Entzündungshemmende arylnitrilverbindungen
WO2007027012A1 (en) 2005-07-18 2007-03-08 Samsung Electronics Co., Ltd. Video coding method and apparatus for reducing mismatch between encoder and decoder
JP2009502864A (ja) 2005-07-27 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア 殺菌性の５−メチル−６−フェニルトリアゾロピリミジニルアミン
MX2008000357A (es) 2005-07-27 2008-03-07 Basf Ag 6-feniltriazolopirimidinilaminas fungicidas.
JP2009502863A (ja) 2005-07-27 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア ６−フェニル−ピラゾロピリミジン−７−イルアミン殺菌剤
WO2007044441A2 (en) 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
AU2007302245A1 (en) 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
JP2010505881A (ja) 2006-10-05 2010-02-25 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物
US8173661B2 (en) 2006-11-08 2012-05-08 The Rockefeller University Alpha-IIB-beta-3 inhibitors and uses thereof
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
BRPI0806347A2 (pt) 2007-01-19 2011-09-06 Basf Se misturas fungicidas, agente fungicida, método para combater fungos nocivos fitopagênicos, semente, e, processo para preparar um agente
WO2008092836A2 (en) 2007-01-30 2008-08-07 Basf Se Method for improving plant health
BRPI0809045A2 (pt) 2007-03-23 2014-09-02 Basf Se Combinações de substância ativa, uso de combinações de substância ativa, métodos para combater fungos fitopatogênicos indesejáveis, para preparar agentes pesticidas, e para tratar sementes, e, produto de revestimento de semente
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2274308A1 (en) 2008-04-04 2011-01-19 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
US20100099561A1 (en) 2008-10-15 2010-04-22 E.I. Du Pont De Nemours And Company Heterobicyclic alkylthio-bridged isoxazolines
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
JPWO2012011592A1 (ja) 2010-07-23 2013-09-09 武田薬品工業株式会社 複素環化合物およびその用途
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2013177538A2 (en) 2012-05-24 2013-11-28 Colorado State University Research Foundation Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
EP3041474B1 (en) 2013-09-05 2020-03-18 Genentech, Inc. Antiproliferative compounds
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
AU2015251207B2 (en) 2014-04-23 2019-08-22 Mitsubishi Tanabe Pharma Corporation Novel bicyclic or tricyclic heterocyclic compound
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
JP6791717B2 (ja) 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
JP2017091808A (ja) 2015-11-10 2017-05-25 株式会社フジクラ 酸化物超電導線材の製造方法及び超電導コイルの製造方法
WO2017112678A1 (en) 2015-12-21 2017-06-29 Rima Mcleod Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CR20190157A (es) 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares
CN106749271B (zh) 2016-12-07 2019-04-05 青岛科技大学 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途
WO2018213365A1 (en) 2017-05-15 2018-11-22 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
AU2018331456B2 (en) 2017-09-15 2020-10-08 Chinook Therapeutics, Inc. Pyrazolopyrimidinone compounds and uses thereof
CN118161500A (zh) 2019-11-25 2024-06-11 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516321A (ja) 2009-01-27 2012-07-19 武田薬品工業株式会社 デルター５−デサチュラーゼ阻害薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS Medicinal Chemistry Letters，2016年，Vol.7，pp.868-872
PLOS ONE，2016年，Vol.11, No.11，DOI:10.1371/journal.pone.0166198

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023078418A (ja) * 2019-11-25 2023-06-06 アムジエン・インコーポレーテツド デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法
JP7698676B2 (ja) 2019-11-25 2025-06-25 アムジエン・インコーポレーテツド デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法

Also Published As

Publication number Publication date
CL2023002486A1 (es) 2024-01-12
CN114728167B (zh) 2024-03-19
CL2022001357A1 (es) 2023-03-10
IL293191B1 (en) 2025-05-01
WO2021108408A1 (en) 2021-06-03
BR112022010054A2 (pt) 2022-08-16
IL293191A (en) 2022-07-01
MX2022006281A (es) 2022-06-08
CN114728167A (zh) 2022-07-08
PH12022551282A1 (en) 2023-11-29
AU2020392087A1 (en) 2022-06-09
JOP20220125A1 (ar) 2023-01-30
US12448396B2 (en) 2025-10-21
TWI867822B (zh) 2024-12-21
TW202409042A (zh) 2024-03-01
TWI815061B (zh) 2023-09-11
IL293191B2 (en) 2025-09-01
US20210188874A1 (en) 2021-06-24
KR20220106159A (ko) 2022-07-28
US20230159560A1 (en) 2023-05-25
KR102598203B1 (ko) 2023-11-03
US11512097B2 (en) 2022-11-29
TW202132317A (zh) 2021-09-01
JP2022549739A (ja) 2022-11-28
CR20220308A (es) 2022-08-04
AR120556A1 (es) 2022-02-23
AU2020392087B2 (en) 2025-10-23
PE20231097A1 (es) 2023-07-18
KR20230154292A (ko) 2023-11-07
CA3162281A1 (en) 2021-06-03
SA522432710B1 (ar) 2025-05-29
CN118161500A (zh) 2024-06-11
JP7698676B2 (ja) 2025-06-25
CO2022008690A2 (es) 2022-06-30
EP4065223A1 (en) 2022-10-05
JP2023078418A (ja) 2023-06-06
UY38971A (es) 2021-06-30
US20210221824A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
JP7254246B2 (ja) デルタ－５デサチュラーゼ阻害剤としての複素環式化合物及び使用方法
JP5808869B2 (ja) 二環式ピペラジン化合物
JP5546693B2 (ja) ピラゾロキノリン誘導体
TWI485151B (zh) 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
PT2152712E (pt) Compostos amino-heterocíclicos
WO2023091726A1 (en) Inhibitors of cyclin‑dependent kinase 12 (cdk12)
JP2019534324A (ja) Ｐｄｅ１阻害剤としてのイミダゾピラジノン、ピラゾロピリミジノンおよびピラゾロピリジノン
JP7638987B2 (ja) デルタ－５デサチュラーゼ阻害剤としての複素環式化合物、及び使用法
EA048401B1 (ru) Гетероциклические соединения в качестве ингибиторов дельта-5-десатуразы и способы применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221111

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230328

R150 Certificate of patent or registration of utility model

Ref document number: 7254246

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150